Skip to content
2000
image of Driver Genes and Genomic Instability Predict the Incidence and Outcome of Brain Metastases

Abstract

Introduction

The incidence of brain metastases in patients diagnosed with advanced lung cancer is high, drawing significant attention to the risk factors associated with this progression.

Methods

A total of 252 advanced non-small cell lung cancer (NSCLC) patients with brain metastases were enrolled in this study between July 2018 and December 2023 from our hospital. Additionally, driver genes, including EGFR, ALK, ROS1, KRAS, and RET, were documented. Next-generation targeted sequencing of a 168-gene panel was conducted on all collected samples to explore the association between tumor genomic complexity and risk factors for NSCLC with brain metastases.

Results

Among 252 lung cancer patients with brain metastases enrolled in this research, the most prevalent driver gene was EGFR, accounting for 39.29% (99 patients). Other driver gene mutations, such as KRAS, ALK, ROS1, and RET, accounted for 3.57%, 7.14%, 2.78%, and 0.4%, respectively. Kaplan-Meier analysis showed that patients with EGFR mutations had a more favorable overall survival (OS) compared to those without the mutation (P < 0.0001). Additionally, patients with ALK fusions had longer survival times compared to those with wild-type genes (P = 0.0021). In this study, patients were divided into two groups based on the presence or absence of copy-number alterations. Further survival analysis revealed that patients with copy-number alterations experienced significantly shorter overall survival compared to the control group (P = 0.041).

Discussion

This study underscores the crucial role of driver mutations and genomic instability in advanced NSCLC with brain metastases, where EGFR and ALK alterations are linked to better survival. In contrast, high genomic complexity is associated with worse outcomes.

Conclusion

Driver gene mutations are present in more than half of the patients with central nervous system (CNS) failure. Genomic instability, characterized by the number of co-occurring mutated genes and copy-number alterations, is a risk factor associated with shorter survival time.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ccdt/10.2174/0115680096385277250818184435
2025-09-03
2025-11-04

  • From This Site

    /content/journals/ccdt/10.2174/0115680096385277250818184435
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Torre L.A. Bray F. Siegel R.L. Ferlay J. Lortet-Tieulent J. Jemal A. Global cancer statistics, 2012. CA Cancer J. Clin. 2015 65 2 87 108 10.3322/caac.21262 25651787
    [Google Scholar]
  2. Sung H. Ferlay J. Siegel R.L. Laversanne M. Soerjomataram I. Jemal A. Bray F. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021 71 3 209 249 10.3322/caac.21660 33538338
    [Google Scholar]
  3. Bray F. Laversanne M. Sung H. Ferlay J. Siegel R.L. Soerjomataram I. Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2024 74 3 229 263 10.3322/caac.21834 38572751
    [Google Scholar]
  4. Li Q. Xia C. Li H. Yan X. Yang F. Cao M. Zhang S. Teng Y. He S. Cao M. Chen W. Disparities in 36 cancers across 185 countries: Secondary analysis of global cancer statistics. Front. Med. 2024 18 5 911 920 10.1007/s11684‑024‑1058‑6 39167345
    [Google Scholar]
  5. Relli V. Trerotola M. Guerra E. Alberti S. Abandoning the notion of non-small cell lung cancer. Trends Mol. Med. 2019 25 7 585 594 10.1016/j.molmed.2019.04.012 31155338
    [Google Scholar]
  6. Hirsch F.R. Scagliotti G.V. Mulshine J.L. Kwon R. Curran W.J. Wu Y.L. Paz-Ares L. Lung cancer: Current therapies and new targeted treatments. Lancet 2017 389 10066 299 311 10.1016/S0140‑6736(16)30958‑8 27574741
    [Google Scholar]
  7. Blume-Jensen P. Hunter T. Oncogenic kinase signalling. Nature 2001 411 6835 355 365 10.1038/35077225 11357143
    [Google Scholar]
  8. Tsao A.S. Scagliotti G.V. Bunn P.A. Carbone D.P. Warren G.W. Bai C. de Koning H.J. Yousaf-Khan A.U. McWilliams A. Tsao M.S. Adusumilli P.S. Rami-Porta R. Asamura H. Van Schil P.E. Darling G.E. Ramalingam S.S. Gomez D.R. Rosenzweig K.E. Zimmermann S. Peters S. Ignatius Ou S.H. Reungwetwattana T. Jänne P.A. Mok T.S. Wakelee H.A. Pirker R. Mazières J. Brahmer J.R. Zhou Y. Herbst R.S. Papadimitrakopoulou V.A. Redman M.W. Wynes M.W. Gandara D.R. Kelly R.J. Hirsch F.R. Pass H.I. Scientific advances in lung cancer 2015. J. Thorac. Oncol. 2016 11 5 613 638 10.1016/j.jtho.2016.03.012 27013409
    [Google Scholar]
  9. Lynch T.J. Bell D.W. Sordella R. Gurubhagavatula S. Okimoto R.A. Brannigan B.W. Harris P.L. Haserlat S.M. Supko J.G. Haluska F.G. Louis D.N. Christiani D.C. Settleman J. Haber D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004 350 21 2129 2139 10.1056/NEJMoa040938 15118073
    [Google Scholar]
  10. Paez J.G. Jänne P.A. Lee J.C. Tracy S. Greulich H. Gabriel S. Herman P. Kaye F.J. Lindeman N. Boggon T.J. Naoki K. Sasaki H. Fujii Y. Eck M.J. Sellers W.R. Johnson B.E. Meyerson M. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004 304 5676 1497 1500 10.1126/science.1099314 15118125
    [Google Scholar]
  11. Pao W. Miller V. Zakowski M. Doherty J. Politi K. Sarkaria I. Singh B. Heelan R. Rusch V. Fulton L. Mardis E. Kupfer D. Wilson R. Kris M. Varmus H. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA 2004 101 36 13306 13311 10.1073/pnas.0405220101 15329413
    [Google Scholar]
  12. Lee C.K. Wu Y.L. Ding P.N. Lord S.J. Inoue A. Zhou C. Mitsudomi T. Rosell R. Pavlakis N. Links M. Gebski V. Gralla R.J. Yang J.C.H. Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with egfr tyrosine kinase inhibitors versus chemotherapy in EGFR -Mutant lung cancer: A meta-analysis. J. Clin. Oncol. 2015 33 17 1958 1965 10.1200/JCO.2014.58.1736 25897154
    [Google Scholar]
  13. Rosell R. Carcereny E. Gervais R. Vergnenegre A. Massuti B. Felip E. Palmero R. Garcia-Gomez R. Pallares C. Sanchez J.M. Porta R. Cobo M. Garrido P. Longo F. Moran T. Insa A. De Marinis F. Corre R. Bover I. Illiano A. Dansin E. de Castro J. Milella M. Reguart N. Altavilla G. Jimenez U. Provencio M. Moreno M.A. Terrasa J. Muñoz-Langa J. Valdivia J. Isla D. Domine M. Molinier O. Mazieres J. Baize N. Garcia-Campelo R. Robinet G. Rodriguez-Abreu D. Lopez-Vivanco G. Gebbia V. Ferrera-Delgado L. Bombaron P. Bernabe R. Bearz A. Artal A. Cortesi E. Rolfo C. Sanchez-Ronco M. Drozdowskyj A. Queralt C. de Aguirre I. Ramirez J.L. Sanchez J.J. Molina M.A. Taron M. Paz-Ares L. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 13 3 239 246 10.1016/S1470‑2045(11)70393‑X 22285168
    [Google Scholar]
  14. Ramalingam S.S. Yang J.C.H. Lee C.K. Kurata T. Kim D.W. John T. Nogami N. Ohe Y. Mann H. Rukazenkov Y. Ghiorghiu S. Stetson D. Markovets A. Barrett J.C. Thress K.S. Jänne P.A. Osimertinib as first-line treatment of EGFR mutation–positive advanced non–small-cell lung cancer. J. Clin. Oncol. 2018 36 9 841 849 10.1200/JCO.2017.74.7576 28841389
    [Google Scholar]
  15. Zhong W.Z. Yan H.H. Chen K.N. Chen C. Gu C.D. Wang J. Yang X.N. Mao W.M. Wang Q. Qiao G.B. Cheng Y. Xu L. Wang C.L. Chen M.W. Kang X.Z. Yan W.P. Liao R.Q. Yang J.J. Zhang X.C. Liu S.Y. Zhou Q. Wu Y.L. Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: Final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial. Signal Transduct. Target. Ther. 2023 8 1 76 10.1038/s41392‑022‑01286‑3 36823150
    [Google Scholar]
  16. Ji H. Li D. Chen L. Shimamura T. Kobayashi S. McNamara K. Mahmood U. Mitchell A. Sun Y. Al-Hashem R. Chirieac L.R. Padera R. Bronson R.T. Kim W. Jänne P.A. Shapiro G.I. Tenen D. Johnson B.E. Weissleder R. Sharpless N.E. Wong K.K. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 2006 9 6 485 495 10.1016/j.ccr.2006.04.022 16730237
    [Google Scholar]
  17. Politi K. Zakowski M.F. Fan P.D. Schonfeld E.A. Pao W. Varmus H.E. Lung adenocarcinomas induced in mice by mutant EGF receptors foundin human lung cancers respondto a tyrosine kinase inhibitor orto down-regulation of the receptors. Genes Dev. 2006 20 11 1496 1510 10.1101/gad.1417406 16705038
    [Google Scholar]
  18. Dai J. Liu X. Li J. Qu T. Cui Y. Jin S. Zhang E. Guo R. Efficacy and safety of antiangiogenic agents or chemotherapy plus EGFR‐TKIs in advanced non‐small cell lung cancer: A systematic review and network meta‐analysis. Thorac. Cancer 2023 14 6 535 543 10.1111/1759‑7714.14783 36594109
    [Google Scholar]
  19. Hosomi Y. Morita S. Sugawara S. Kato T. Fukuhara T. Gemma A. Takahashi K. Fujita Y. Harada T. Minato K. Takamura K. Hagiwara K. Kobayashi K. Nukiwa T. Inoue A. Gefitinib alone versus gefitinib plus chemotherapy for non–small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study. J. Clin. Oncol. 2020 38 2 115 123 10.1200/JCO.19.01488 31682542
    [Google Scholar]
  20. Miyauchi E. Morita S. Nakamura A. Hosomi Y. Watanabe K. Ikeda S. Seike M. Fujita Y. Minato K. Ko R. Harada T. Hagiwara K. Kobayashi K. Nukiwa T. Inoue A. Updated analysis of NEJ009: Gefitinib-alone versus gefitinib plus chemotherapy for non–small-cell lung cancer with mutated EGFR. J. Clin. Oncol. 2022 40 31 3587 3592 10.1200/JCO.21.02911 35960896
    [Google Scholar]
  21. Zhu Y. Zhang Y. Hu X. Wang M. Wang H. Liu Y. PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy. J. Cancer Res. Clin. Oncol. 2022 148 12 3557 3566 10.1007/s00432‑022‑04177‑w 35857126
    [Google Scholar]
  22. Gavrilovic I.T. Posner J.B. Brain metastases: Epidemiology and pathophysiology. J. Neurooncol. 2005 75 1 5 14 10.1007/s11060‑004‑8093‑6 16215811
    [Google Scholar]
  23. Sperduto P.W. Yang T.J. Beal K. Pan H. Brown P.D. Bangdiwala A. Shanley R. Yeh N. Gaspar L.E. Braunstein S. Sneed P. Boyle J. Kirkpatrick J.P. Mak K.S. Shih H.A. Engelman A. Roberge D. Arvold N.D. Alexander B. Awad M.M. Contessa J. Chiang V. Hardie J. Ma D. Lou E. Sperduto W. Mehta M.P. Estimating survival in patients with lung cancer and brain metastases. JAMA Oncol. 2017 3 6 827 831 10.1001/jamaoncol.2016.3834 27892978
    [Google Scholar]
  24. Brown L.J. Yeo N. Gee H. Kong B.Y. Hau E. da Silva I.P. Nagrial A. Immune checkpoint inhibitors +/− chemotherapy for patients with NSCLC and brain metastases: A systematic review and network meta‐analysis. Thorac. Cancer 2025 16 2 15510 10.1111/1759‑7714.15510 39843204
    [Google Scholar]
  25. Buriolla S. Pelizzari G. Corvaja C. Alberti M. Targato G. Bortolot M. Torresan S. Cortiula F. Fasola G. Follador A. Immunotherapy in NSCLC patients with brain metastases. Int. J. Mol. Sci. 2022 23 13 7068 10.3390/ijms23137068 35806080
    [Google Scholar]
  26. Nayak L. Lee E.Q. Wen P.Y. Epidemiology of brain metastases. Curr. Oncol. Rep. 2012 14 1 48 54 10.1007/s11912‑011‑0203‑y 22012633
    [Google Scholar]
  27. Achrol A.S. Rennert R.C. Anders C. Soffietti R. Ahluwalia M.S. Nayak L. Peters S. Arvold N.D. Harsh G.R. Steeg P.S. Chang S.D. Brain metastases. Nat. Rev. Dis. Primers 2019 5 1 5 10.1038/s41572‑018‑0055‑y 30655533
    [Google Scholar]
  28. Dempke W.C. Edvardsen K. Lu S. Reinmuth N. Reck M. Inoue A. Brain metastases in NSCLC - are TKIs changing the treatment strategy? Anticancer Res. 2015 35 11 5797 5806 26504000
    [Google Scholar]
  29. Taillibert S. Le Rhun É. Epidemiology of brain metastases Cancer Radiother. 2015 19 1 3 9 10.1016/j.canrad.2014.11.001 25636729
    [Google Scholar]
  30. Tomasini P. Serdjebi C. Khobta N. Metellus P. Ouafik L.H. Nanni I. Greillier L. Loundou A. Fina F. Mascaux C. Barlesi F. EGFR and KRAS mutations predict the incidence and outcome of brain metastases in non-small cell lung cancer. Int. J. Mol. Sci. 2016 17 12 2132 10.3390/ijms17122132 27999344
    [Google Scholar]
  31. Patil T. Smith D.E. Bunn P.A. Aisner D.L. Le A.T. Hancock M. Purcell W.T. Bowles D.W. Camidge D.R. Doebele R.C. The incidence of brain metastases in stage IV ROS1-rearranged non–small cell lung cancer and rate of central nervous system progression on crizotinib. J. Thorac. Oncol. 2018 13 11 1717 1726 10.1016/j.jtho.2018.07.001 29981925
    [Google Scholar]
  32. Turajlic S. Xu H. Litchfield K. Rowan A. Horswell S. Chambers T. O’Brien T. Lopez J.I. Watkins T.B.K. Nicol D. Stares M. Challacombe B. Hazell S. Chandra A. Mitchell T.J. Au L. Eichler-Jonsson C. Jabbar F. Soultati A. Chowdhury S. Rudman S. Lynch J. Fernando A. Stamp G. Nye E. Stewart A. Xing W. Smith J.C. Escudero M. Huffman A. Matthews N. Elgar G. Phillimore B. Costa M. Begum S. Ward S. Salm M. Boeing S. Fisher R. Spain L. Navas C. Grönroos E. Hobor S. Sharma S. Aurangzeb I. Lall S. Polson A. Varia M. Horsfield C. Fotiadis N. Pickering L. Schwarz R.F. Silva B. Herrero J. Luscombe N.M. Jamal-Hanjani M. Rosenthal R. Birkbak N.J. Wilson G.A. Pipek O. Ribli D. Krzystanek M. Csabai I. Szallasi Z. Gore M. McGranahan N. Van Loo P. Campbell P. Larkin J. Swanton C. Deterministic evolutionary trajectories influence primary tumor growth: TRACERx renal. Cell 2018 173 3 595 610.e11 10.1016/j.cell.2018.03.043 29656894
    [Google Scholar]
  33. Jamal-Hanjani M. Wilson G.A. McGranahan N. Birkbak N.J. Watkins T.B.K. Veeriah S. Shafi S. Johnson D.H. Mitter R. Rosenthal R. Salm M. Horswell S. Escudero M. Matthews N. Rowan A. Chambers T. Moore D.A. Turajlic S. Xu H. Lee S.M. Forster M.D. Ahmad T. Hiley C.T. Abbosh C. Falzon M. Borg E. Marafioti T. Lawrence D. Hayward M. Kolvekar S. Panagiotopoulos N. Janes S.M. Thakrar R. Ahmed A. Blackhall F. Summers Y. Shah R. Joseph L. Quinn A.M. Crosbie P.A. Naidu B. Middleton G. Langman G. Trotter S. Nicolson M. Remmen H. Kerr K. Chetty M. Gomersall L. Fennell D.A. Nakas A. Rathinam S. Anand G. Khan S. Russell P. Ezhil V. Ismail B. Irvin-Sellers M. Prakash V. Lester J.F. Kornaszewska M. Attanoos R. Adams H. Davies H. Dentro S. Taniere P. O’Sullivan B. Lowe H.L. Hartley J.A. Iles N. Bell H. Ngai Y. Shaw J.A. Herrero J. Szallasi Z. Schwarz R.F. Stewart A. Quezada S.A. Le Quesne J. Van Loo P. Dive C. Hackshaw A. Swanton C. Tracking the evolution of non–small-cell lung cancer. N. Engl. J. Med. 2017 376 22 2109 2121 10.1056/NEJMoa1616288 28445112
    [Google Scholar]
  34. Biswas D. Birkbak N.J. Rosenthal R. Hiley C.T. Lim E.L. Papp K. Boeing S. Krzystanek M. Djureinovic D. La Fleur L. Greco M. Döme B. Fillinger J. Brunnström H. Wu Y. Moore D.A. Skrzypski M. Abbosh C. Litchfield K. Al Bakir M. Watkins T.B.K. Veeriah S. Wilson G.A. Jamal-Hanjani M. Moldvay J. Botling J. Chinnaiyan A.M. Micke P. Hackshaw A. Bartek J. Csabai I. Szallasi Z. Herrero J. McGranahan N. Swanton C. A clonal expression biomarker associates with lung cancer mortality. Nat. Med. 2019 25 10 1540 1548 10.1038/s41591‑019‑0595‑z 31591602
    [Google Scholar]
  35. Zito Marino F. Pagliuca F. Ronchi A. Cozzolino I. Montella M. Berretta M. Errico M.E. Donofrio V. Bianco R. Franco R. NTRK fusions, from the diagnostic algorithm to innovative treatment in the era of precision medicine. Int. J. Mol. Sci. 2020 21 10 3718 10.3390/ijms21103718 32466202
    [Google Scholar]
  36. Sheikine Y. Kuo F.C. Lindeman N.I. Clinical and technical aspects of genomic diagnostics for precision oncology. J. Clin. Oncol. 2017 35 9 929 933 10.1200/JCO.2016.70.7539 28297627
    [Google Scholar]
  37. Zhou C. Wu Y.L. Chen G. Feng J. Liu X.Q. Wang C. Zhang S. Wang J. Zhou S. Ren S. Lu S. Zhang L. Hu C. Hu C. Luo Y. Chen L. Ye M. Huang J. Zhi X. Zhang Y. Xiu Q. Ma J. Zhang L. You C. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011 12 8 735 742 10.1016/S1470‑2045(11)70184‑X 21783417
    [Google Scholar]
  38. Mitsudomi T. Morita S. Yatabe Y. Negoro S. Okamoto I. Tsurutani J. Seto T. Satouchi M. Tada H. Hirashima T. Asami K. Katakami N. Takada M. Yoshioka H. Shibata K. Kudoh S. Shimizu E. Saito H. Toyooka S. Nakagawa K. Fukuoka M. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol. 2010 11 2 121 128 10.1016/S1470‑2045(09)70364‑X 20022809
    [Google Scholar]
  39. Wu Y.L. Ahn M.J. Garassino M.C. Han J.Y. Katakami N. Kim H.R. Hodge R. Kaur P. Brown A.P. Ghiorghiu D. Papadimitrakopoulou V.A. Mok T.S.K. CNS efficacy of osimertinib in patients with t790m-positive advanced non–small-cell lung cancer: Data from a randomized phase III trial (AURA3). J. Clin. Oncol. 2018 36 26 2702 2709 10.1200/JCO.2018.77.9363 30059262
    [Google Scholar]
  40. Heon S. Yeap B.Y. Britt G.J. Costa D.B. Rabin M.S. Jackman D.M. Johnson B.E. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin. Cancer Res. 2010 16 23 5873 5882 10.1158/1078‑0432.CCR‑10‑1588 21030498
    [Google Scholar]
  41. Lee Y.J. Choi H.J. Kim S.K. Chang J. Moon J.W. Park I.K. Kim J.H. Cho B.C. Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall‐cell lung cancer. Cancer 2010 116 5 1336 1343 10.1002/cncr.24877 20066717
    [Google Scholar]
  42. Sacks P. Rahman M. Epidemiology of brain metastases. Neurosurg. Clin. N. Am. 2020 31 4 481 488 10.1016/j.nec.2020.06.001 32921345
    [Google Scholar]
  43. Cagney D.N. Martin A.M. Catalano P.J. Redig A.J. Lin N.U. Lee E.Q. Wen P.Y. Dunn I.F. Bi W.L. Weiss S.E. Haas-Kogan D.A. Alexander B.M. Aizer A.A. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: A population-based study. Neuro-oncol. 2017 19 11 1511 1521 10.1093/neuonc/nox077 28444227
    [Google Scholar]
  44. Zimm S. Wampler G.L. Stablein D. Hazra T. Young H.F. Intracerebral metastases in solid-tumor patients: Natural history and results of treatment. Cancer 1981 48 2 384 394 10.1002/1097‑0142(19810715)48:2<384:AID‑CNCR2820480227>3.0.CO;2‑8 7237407
    [Google Scholar]
  45. Kris M.G. Natale R.B. Herbst R.S. Lynch T.J. Prager D. Belani C.P. Schiller J.H. Kelly K. Spiridonidis H. Sandler A. Albain K.S. Cella D. Wolf M.K. Averbuch S.D. Ochs J.J. Kay A.C. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 2003 290 16 2149 2158 10.1001/jama.290.16.2149 14570950
    [Google Scholar]
  46. Pérez-Soler R. Chachoua A. Hammond L.A. Rowinsky E.K. Huberman M. Karp D. Rigas J. Clark G.M. Santabárbara P. Bonomi P. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. J. Clin. Oncol. 2004 22 16 3238 3247 10.1200/JCO.2004.11.057 15310767
    [Google Scholar]
  47. Gomez-Roca C. Raynaud C.M. Penault-Llorca F. Mercier O. Commo F. Morat L. Sabatier L. Dartevelle P. Taranchon E. Besse B. Validire P. Italiano A. Soria J.C. Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites. J. Thorac. Oncol. 2009 4 10 1212 1220 10.1097/JTO.0b013e3181b44321 19687761
    [Google Scholar]
  48. Wang H. Wang Z. Zhang G. Zhang M. Zhang X. Li H. Zheng X. Ma Z. Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations. Cancer Med. 2020 9 2 487 495 10.1002/cam4.2706 31769228
    [Google Scholar]
  49. Vogelstein B. Papadopoulos N. Velculescu V.E. Zhou S. Diaz L.A. Kinzler K.W. Cancer genome landscapes. Science 2013 339 6127 1546 1558 10.1126/science.1235122 23539594
    [Google Scholar]
  50. Yun J. Rago C. Cheong I. Pagliarini R. Angenendt P. Rajagopalan H. Schmidt K. Willson J.K.V. Markowitz S. Zhou S. Diaz L.A. Velculescu V.E. Lengauer C. Kinzler K.W. Vogelstein B. Papadopoulos N. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 2009 325 5947 1555 1559 10.1126/science.1174229 19661383
    [Google Scholar]
  51. Ying H. Kimmelman A.C. Lyssiotis C.A. Hua S. Chu G.C. Fletcher-Sananikone E. Locasale J.W. Son J. Zhang H. Coloff J.L. Yan H. Wang W. Chen S. Viale A. Zheng H. Paik J. Lim C. Guimaraes A.R. Martin E.S. Chang J. Hezel A.F. Perry S.R. Hu J. Gan B. Xiao Y. Asara J.M. Weissleder R. Wang Y.A. Chin L. Cantley L.C. DePinho R.A. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 2012 149 3 656 670 10.1016/j.cell.2012.01.058 22541435
    [Google Scholar]
  52. Deeken J.F. Löscher W. The blood-brain barrier and cancer: Transporters, treatment, and Trojan horses. Clin. Cancer Res. 2007 13 6 1663 1674 10.1158/1078‑0432.CCR‑06‑2854 17363519
    [Google Scholar]
  53. Wrobel J.K. Toborek M. Blood-brain barrier remodeling during brain metastasis formation. Mol. Med. 2016 22 1 32 40 10.2119/molmed.2015.00207 26837070
    [Google Scholar]
  54. Kim E.S. Olmutinib: First Global Approval. Drugs 2016 76 11 1153 1157 10.1007/s40265‑016‑0606‑z 27357069
    [Google Scholar]
  55. Zhang B. Zhang L. Yue D. Li C. Zhang H. Ye J. Gao L. Zhao X. Chen C. Huo Y. Pang C. Li Y. Chen Y. Chuai S. Zhang Z. Giaccone G. Wang C. Genomic characteristics in Chinese non-small cell lung cancer patients and its value in prediction of postoperative prognosis. Transl. Lung Cancer Res. 2020 9 4 1187 1201 10.21037/tlcr‑19‑664 32953497
    [Google Scholar]
  56. Camidge D.R. Pao W. Sequist L.V. Acquired resistance to TKIs in solid tumours: Learning from lung cancer. Nat. Rev. Clin. Oncol. 2014 11 8 473 481 10.1038/nrclinonc.2014.104 24981256
    [Google Scholar]
  57. Mok T.S. Wu Y.L. Ahn M.J. Garassino M.C. Kim H.R. Ramalingam S.S. Shepherd F.A. He Y. Akamatsu H. Theelen W.S.M.E. Lee C.K. Sebastian M. Templeton A. Mann H. Marotti M. Ghiorghiu S. Papadimitrakopoulou V.A. Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer. N. Engl. J. Med. 2017 376 7 629 640 10.1056/NEJMoa1612674 27959700
    [Google Scholar]
  58. Leonetti A. Sharma S. Minari R. Perego P. Giovannetti E. Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br. J. Cancer 2019 121 9 725 737 10.1038/s41416‑019‑0573‑8 31564718
    [Google Scholar]
  59. Yang Z. Yang N. Ou Q. Xiang Y. Jiang T. Wu X. Bao H. Tong X. Wang X. Shao Y.W. Liu Y. Wang Y. Zhou C. Investigating novel resistance mechanisms to third-generation egfr tyrosine kinase inhibitor osimertinib in non–small cell lung cancer patients. Clin. Cancer Res. 2018 24 13 3097 3107 10.1158/1078‑0432.CCR‑17‑2310 29506987
    [Google Scholar]
  60. Niederst M.J. Hu H. Mulvey H.E. Lockerman E.L. Garcia A.R. Piotrowska Z. Sequist L.V. Engelman J.A. The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin. Cancer Res. 2015 21 17 3924 3933 10.1158/1078‑0432.CCR‑15‑0560 25964297
    [Google Scholar]
  61. Blakely C.M. Watkins T.B.K. Wu W. Gini B. Chabon J.J. McCoach C.E. McGranahan N. Wilson G.A. Birkbak N.J. Olivas V.R. Rotow J. Maynard A. Wang V. Gubens M.A. Banks K.C. Lanman R.B. Caulin A.F. St John J. Cordero A.R. Giannikopoulos P. Simmons A.D. Mack P.C. Gandara D.R. Husain H. Doebele R.C. Riess J.W. Diehn M. Swanton C. Bivona T.G. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat. Genet. 2017 49 12 1693 1704 10.1038/ng.3990 29106415
    [Google Scholar]
  62. Kohno T. Nakaoku T. Tsuta K. Tsuchihara K. Matsumoto S. Yoh K. Goto K. Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. Transl. Lung Cancer Res. 2015 4 2 156 164 10.3978/j.issn.2218‑6751.2014.11.11 25870798
    [Google Scholar]
  63. Kohno T. Ichikawa H. Totoki Y. Yasuda K. Hiramoto M. Nammo T. Sakamoto H. Tsuta K. Furuta K. Shimada Y. Iwakawa R. Ogiwara H. Oike T. Enari M. Schetter A.J. Okayama H. Haugen A. Skaug V. Chiku S. Yamanaka I. Arai Y. Watanabe S. Sekine I. Ogawa S. Harris C.C. Tsuda H. Yoshida T. Yokota J. Shibata T. KIF5B-RET fusions in lung adenocarcinoma. Nat. Med. 2012 18 3 375 377 10.1038/nm.2644 22327624
    [Google Scholar]
  64. Takeuchi K. Soda M. Togashi Y. Suzuki R. Sakata S. Hatano S. Asaka R. Hamanaka W. Ninomiya H. Uehara H. Lim Choi Y. Satoh Y. Okumura S. Nakagawa K. Mano H. Ishikawa Y. RET, ROS1 and ALK fusions in lung cancer. Nat. Med. 2012 18 3 378 381 10.1038/nm.2658 22327623
    [Google Scholar]
  65. Lipson D. Capelletti M. Yelensky R. Otto G. Parker A. Jarosz M. Curran J.A. Balasubramanian S. Bloom T. Brennan K.W. Donahue A. Downing S.R. Frampton G.M. Garcia L. Juhn F. Mitchell K.C. White E. White J. Zwirko Z. Peretz T. Nechushtan H. Soussan-Gutman L. Kim J. Sasaki H. Kim H.R. Park S. Ercan D. Sheehan C.E. Ross J.S. Cronin M.T. Jänne P.A. Stephens P.J. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat. Med. 2012 18 3 382 384 10.1038/nm.2673 22327622
    [Google Scholar]
  66. Ju Y.S. Lee W.C. Shin J.Y. Lee S. Bleazard T. Won J.K. Kim Y.T. Kim J.I. Kang J.H. Seo J.S. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res. 2012 22 3 436 445 10.1101/gr.133645.111 22194472
    [Google Scholar]
  67. Drilon A. Rekhtman N. Arcila M. Wang L. Ni A. Albano M. Van Voorthuysen M. Somwar R. Smith R.S. Montecalvo J. Plodkowski A. Ginsberg M.S. Riely G.J. Rudin C.M. Ladanyi M. Kris M.G. Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: An open-label, single-centre, phase 2, single-arm trial. Lancet Oncol. 2016 17 12 1653 1660 10.1016/S1470‑2045(16)30562‑9 27825636
    [Google Scholar]
  68. Yoh K. Seto T. Satouchi M. Nishio M. Yamamoto N. Murakami H. Nogami N. Matsumoto S. Kohno T. Tsuta K. Tsuchihara K. Ishii G. Nomura S. Sato A. Ohtsu A. Ohe Y. Goto K. Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): An open-label, multicentre phase 2 trial. Lancet Respir. Med. 2017 5 1 42 50 10.1016/S2213‑2600(16)30322‑8 27825616
    [Google Scholar]
  69. Lee S.H. Lee J.K. Ahn M.J. Kim D.W. Sun J.M. Keam B. Kim T.M. Heo D.S. Ahn J.S. Choi Y.L. Min H.S. Jeon Y.K. Park K. Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: A phase II clinical trial. Ann. Oncol. 2017 28 2 292 297 10.1093/annonc/mdw559 27803005
    [Google Scholar]
  70. Plenker D. Riedel M. Brägelmann J. Dammert M.A. Chauhan R. Knowles P.P. Lorenz C. Keul M. Bührmann M. Pagel O. Tischler V. Scheel A.H. Schütte D. Song Y. Stark J. Mrugalla F. Alber Y. Richters A. Engel J. Leenders F. Heuckmann J.M. Wolf J. Diebold J. Pall G. Peifer M. Aerts M. Gevaert K. Zahedi R.P. Buettner R. Shokat K.M. McDonald N.Q. Kast S.M. Gautschi O. Thomas R.K. Sos M.L. Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors. Sci. Transl. Med. 2017 9 394 eaah6144 10.1126/scitranslmed.aah6144 28615362
    [Google Scholar]
  71. Drilon A. Li G. Dogan S. Gounder M. Shen R. Arcila M. Wang L. Hyman D.M. Hechtman J. Wei G. Cam N.R. Christiansen J. Luo D. Maneval E.C. Bauer T. Patel M. Liu S.V. Ou S.H.I. Farago A. Shaw A. Shoemaker R.F. Lim J. Hornby Z. Multani P. Ladanyi M. Berger M. Katabi N. Ghossein R. Ho A.L. What hides behind the MASC: Clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC). Ann. Oncol. 2016 27 5 920 926 10.1093/annonc/mdw042 26884591
    [Google Scholar]
  72. Qin L. Guo T. Yang H. Deng P. Gu Q. Liu C. Wu M. Lizaso A. Li B. Zhang S. Chen Z. Hu C. The utility of sputum supernatant as an alternative liquid biopsy specimen for next-generation sequencing-based somatic variation profiling. Ann. Transl. Med. 2022 10 8 462 10.21037/atm‑22‑1297 35571392
    [Google Scholar]
  73. Lin Z. Li Y. Tang S. Deng Q. Jiang J. Zhou C. Comparative analysis of genomic profiles between tissue-based and plasma-based next-generation sequencing in patients with non-small cell lung cancer. Lung Cancer 2023 182 107282 10.1016/j.lungcan.2023.107282 37392713
    [Google Scholar]
  74. Xing P. Yang N. Hu X. Mu Y. Wang S. Guo Y. Hao X. Hu X. Zhang X. Li J. The clinical significance of RET gene fusion among Chinese patients with lung cancer. Transl. Cancer Res. 2020 9 10 6455 6463 10.21037/tcr‑20‑754 35117253
    [Google Scholar]
  75. Shi L. Guo L. Tao H. Meng Q. Tong L. Tang J. Li K. Zhang S. Liu Z. Genetic profiling of circulating cell‐free DNA from cerebrospinal fluid and paired plasma in ALK‐ positive lung cancer with brain metastases. Thorac. Cancer 2023 14 19 1883 1893 10.1111/1759‑7714.14936 37287428
    [Google Scholar]
  76. Ma S. Shi M. Chen X. Wang Y. Yang Z. Lizaso A. Li M. Li H. Zhang L. Mao X. Xu X. Song Y. The prognostic value of longitudinal circulating tumor DNA profiling during osimertinib treatment. Transl. Lung Cancer Res. 2021 10 1 326 339 10.21037/tlcr‑20‑371 33569316
    [Google Scholar]
/content/journals/ccdt/10.2174/0115680096385277250818184435
Loading
Driver Genes and Genomic Instability Predict the Incidence and Outcome of Brain Metastases
Bentham Science Publishers ; https://doi.org/10.2174/0115680096385277250818184435
/content/journals/ccdt/10.2174/0115680096385277250818184435
/content/journals/ccdt/10.2174/0115680096385277250818184435
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Research Article
Keywords: genomic instability ; non-small cell lung cancer ; driver gene mutation ; Brain metastases

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test